Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-08-06 00:00:00 ET · period of report 2024-08-02 · accession 0001968202-24-000113 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-08-06 | 2024-08-02 | REGN | STAHL NEIL | EVP Research, Development | M - OptEx | $555.67 | +23.6K | 74.6K | +46% | +$13.13M |
| D | 2024-08-06 | 2024-08-02 | REGN | STAHL NEIL | EVP Research, Development | F - Tax | $1,093.49 | -18.4K | 56.2K | -25% | -$20.17M |
| D | 2024-08-06 | 2024-08-02 | REGN | STAHL NEIL | EVP Research, Development | M - OptEx | $0.00 | -23.6K | 45.0K | -34% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-02 | M | A | 23,638 | $555.67 | 74,637 | D | — | — | |
| 2 | Common | Common Stock | 2024-08-02 | F | D | 18,441 | $1,093.49 | 56,196 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-08-02 | M | D | 23,638 | $0.00 | 45,000 | D | $555.67 · — to 2025-12-16 | 23,638 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |